Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions

被引:118
作者
Kalkman, Deborah N. [1 ,2 ]
Aquino, Melissa [1 ]
Claessen, Bimmer E. [1 ]
Baber, Usman [1 ]
Guedeney, Paul [1 ]
Sorrentino, Sabato [1 ]
Vogel, Birgit [1 ]
de Winter, Robbert J. [2 ]
Sweeny, Joseph [1 ]
Kovacic, Jason C. [1 ]
Shah, Srushti [1 ]
Vijay, Pooja [1 ]
Barman, Nitin [1 ]
Kini, Annapoorna [1 ]
Sharma, Samin [1 ]
Dangas, George D. [1 ]
Mehran, Roxana [1 ]
机构
[1] Icahn Sch Med Mt Sinai Hosp, Ctr Intervent Cardiovasc Res & Clin Trials, One Gustave L Levy Pl Box 1030, New York, NY 10029 USA
[2] Univ Amsterdam, Heart Ctr, Amsterdam Cardiovasc Sci, Dept Clin & Expt Cardiol,Amsterdam UMC, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
关键词
Percutaneous coronary intervention; Inflammation; C-reactive protein; Clinical outcomes; All-cause mortality; C-REACTIVE PROTEIN; DUAL ANTIPLATELET THERAPY; CARDIOVASCULAR EVENTS; ARTERY-DISEASE; FOCUSED UPDATE; ELEVATION; ASSOCIATION; INFARCTION; REDUCTION;
D O I
10.1093/eurheartj/ehy633
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims It remains unknown what percentage of patients treated with percutaneous coronary artery intervention (PCI) have high residual inflammatory risk (RIR). Moreover, the impact of RIR on clinical outcomes has not been established. The objective of this study is to determine the prevalence of patients with persistent high levels of inflammation after PCI and to evaluate clinical outcomes according to inflammatory response. Methods and results This is a retrospective cohort study assessing patients undergoing PCI between 2009 and 2016 with serial inflammatory status assessment from a large, prospective, and single-centre PCI registry. Assessment of inflammation status with at least two high sensitive C-reactive protein (hsCRP) measurements at baseline and follow-up with >4 weeks apart. High RIR was defined as an hsCRP >= 2 mg/L. Patients were divided into four groups: persistent high RIR, increased RIR (first low-, then high hsCRP), attenuated RIR (first high-, then low hsCRP), or persistent low RIR. The primary endpoint was all-cause mortality at 1 year follow-up. Occurrence of myocardial infarction (MI) was assessed as secondary outcome. Seven thousand and twenty-six patients were identified with serial hsCRP measurements (30.8% of all PCI patients). Of these patients 2654 (38%) had persistent high RIR, 719 patients (10%) had increased RIR, 1088 patients (15%) had attenuated RIR, and persistent low RIR was seen in 2565 patients (37%). All-cause mortality at 1 year was 2.6% in patients with persistent high RIR, compared with 1.0% in increased RIR, 0.3% in attenuated RIR, and 0.7% in persistent low RIR patients, P < 0.01. MI at 1 year was observed in 7.5% of persistent high RIR, compared with 6.4% in increased RIR, 4.6% in attenuated RIR, and 4.3% in persistent low RIR, P < 0.01. In an adjusted model, including accounting for diabetes mellitus, acute coronary syndrome, and baseline low-density lipoprotein, results were sustained. Conclusion Persistent high RIR is observed frequently in patients undergoing PCI. In these patients, significantly higher all-cause mortality and MI rates are observed at 1 year follow-up. Residual inflammatory risk in patients undergoing PCI should be identified and treatment options should be further explored.
引用
收藏
页码:4101 / +
页数:9
相关论文
共 27 条
[11]   Sex Differences in Inflammatory Markers and Health Status Among Young Adults With Acute Myocardial Infarction Results From the VIRGO (Variation in Recovery: Role of Gender on Outcomes of Young Acute Myocardial Infarction Patients) Study [J].
Lu, Yuan ;
Zhou, Shengfan ;
Dreyer, Rachel P. ;
Spatz, Erica S. ;
Geda, Mary ;
Lorenze, Nancy P. ;
D'Onofrio, Gail ;
Lichtman, Judith H. ;
Spertus, John A. ;
Ridker, Paul M. ;
Krumholz, Harlan M. .
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2017, 10 (02)
[12]   Preprocedural C-Reactive Protein Predicts Outcomes after Primary Percutaneous Coronary Intervention in Patients with ST-elevation Myocardial Infarction a systematic meta-analysis [J].
Mincu, Raluca-Ileana ;
Janosi, Rolf Alexander ;
Vinereanu, Dragos ;
Rassaf, Tienush ;
Totzeck, Matthias .
SCIENTIFIC REPORTS, 2017, 7
[13]   Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients [J].
Mueller, C ;
Buettner, HJ ;
Hodgson, JM ;
Marsch, S ;
Perruchoud, AP ;
Roskamm, H ;
Neumann, FJ .
CIRCULATION, 2002, 105 (12) :1412-1415
[14]   High-sensitivity C-reactive protein predicts 10-year cardiovascular outcome after percutaneous coronary intervention [J].
Oemrawsingh, Rohit M. ;
Cheng, Jin M. ;
Akkerhuis, K. Martijn ;
Kardys, Isabella ;
Degertekin, Muzaffer ;
van Geuns, Robert-Jan ;
Daemen, Joost ;
Boersma, Eric ;
Serruys, Patrick W. ;
van Domburg, Ron T. .
EUROINTERVENTION, 2016, 12 (03) :345-351
[15]   A Point-of-Care Platelet Function Assay and C-Reactive Protein for Prediction of Major Cardiovascular Events After Drug-Eluting Stent Implantation [J].
Park, Duk-Woo ;
Lee, Seung-Whan ;
Yun, Sung-Cheol ;
Song, Hae-Geun ;
Ahn, Jung-Min ;
Lee, Jong-Young ;
Kim, Won-Jang ;
Kang, Soo-Jin ;
Kim, Young-Hak ;
Lee, Cheol Whan ;
Park, Seong-Wook ;
Park, Seung-Jung .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 58 (25) :2630-2639
[16]   C-Reactive Protein and the Risk of Stent Thrombosis and Cardiovascular Events After Drug-Eluting Stent Implantation [J].
Park, Duk-Woo ;
Yun, Sung-Cheol ;
Lee, Jong-Young ;
Kim, Won-Jang ;
Kang, Soo-Jin ;
Lee, Seung-Whan ;
Kim, Young-Hak ;
Lee, Cheol Whan ;
Kim, Jae-Joong ;
Park, Seong-Wook ;
Park, Seung-Jung .
CIRCULATION, 2009, 120 (20) :1987-U29
[17]   2016 European Guidelines on cardiovascular disease prevention in clinical practice [J].
Piepoli, Massimo F. ;
Hoes, Arno W. ;
Agewall, Stefan ;
Albus, Christian ;
Brotons, Carlos ;
Catapano, Alberico L. ;
Cooney, Marie-Therese ;
Corra, Ugo ;
Cosyns, Bernard ;
Deaton, Christi ;
Graham, Ian ;
Hall, Michael Stephen ;
Hobbs, F. D. Richard ;
Lochen, Maja-Lisa ;
Loellgen, Herbert ;
Marques-Vidal, Pedro ;
Perk, Joep ;
Prescott, Eva ;
Redon, Josep ;
Richter, Dimitrios J. ;
Sattar, Naveed ;
Smulders, Yvo ;
Tiberi, Monica ;
van der Worp, H. Bart ;
van Dis, Ineke ;
Verschuren, W. M. Monique .
EUROPEAN HEART JOURNAL, 2016, 37 (29) :2315-+
[18]   High-sensitivity C-reactive protein levels and health status outcomes after myocardial infarction [J].
Pokharel, Yashashwi ;
Sharma, Puza P. ;
Qintar, Mohammed ;
Lu, Yuan ;
Tang, Yuanyuan ;
Jones, Philip ;
Dreyer, Rachel P. ;
Spertus, John A. .
ATHEROSCLEROSIS, 2017, 266 :16-23
[19]   Prevalence and predictors of elevated high-sensitivity C-reactive protein in post-myocardial infarction patients: Insights from the VIRGO and TRIUMPH registries [J].
Qintar, Mohammed ;
Sharma, Puza P. ;
Pokharel, Yashashwi ;
Tang, Yuanyuan ;
Lu, Yuan ;
Jones, Philip ;
Dreyer, Rachel P. ;
Spertus, John A. .
CLINICAL CARDIOLOGY, 2017, 40 (12) :1205-1211
[20]   Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease [J].
Ridker, P. M. ;
Everett, B. M. ;
Thuren, T. ;
MacFadyen, J. G. ;
Chang, W. H. ;
Ballantyne, C. ;
Fonseca, F. ;
Nicolau, J. ;
Koenig, W. ;
Anker, S. D. ;
Kastelein, J. J. P. ;
Cornel, J. H. ;
Pais, P. ;
Pella, D. ;
Genest, J. ;
Cifkova, R. ;
Lorenzatti, A. ;
Forster, T. ;
Kobalava, Z. ;
Vida-Simiti, L. ;
Flather, M. ;
Shimokawa, H. ;
Ogawa, H. ;
Dellborg, M. ;
Rossi, P. R. F. ;
Troquay, R. P. T. ;
Libby, P. ;
Glynn, R. J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (12) :1119-1131